Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: A multicenter study

Cancer Science

Volumn 102, Issue 2, 2011, Pages 414-418

  Tateishi, Ukihide ^a   Tatsumi, Mitsuaki ^b   Terauchi, Takashi ^c   Ishizawa, Kenichi ^d   Ogura, Michinori ^e   Tobinai, Kensei ^f  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

^e NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RELAPSE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; METABOLIC PARAMETERS; METABOLIC REDUCTION; METABOLISM; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PHANTOM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; REFRACTORY PERIOD; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITROGEN MUSTARD COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; ROC CURVE;

EID: 79952078511     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01802.x     Document Type: Article

References (24)

1. Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results form a phase II multicenter, single-agent study. J Clin Oncol 2008; 26: 204-10.
2. Rummel MJ, Al-Batran SE, Kim SZ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383-9.
3. Robinson KS, Williams ME, Van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473-9.
4. Kahl BS, Bartlett NL, Leonard JP et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Results from a multicenter study. Cancer 2010; 116: 106-14.
5. Ogura M, Taniwaki M, Ando K, et al. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010; 101: 2054-8.
6. Ohmachi K, Ando K, Ogura M, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010; 101: 2059-64.
7. Cheson BD, Horning SJ, Coiffier B et al. Report of international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-53.
8. Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 2005; 35: 186-96.
9. Mikhaeel NG. Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur J Nucl Med Mol Imaging 2006; 33: 22-6.
10. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010; 51: 25-30.
11. Tsukamoto N, Kojima M, Hasegawa M et al. The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on World Health Organization classification. Cancer 2007; 110: 652-9.
12. Elstrom R, Guan L, Baker G et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875-6.
13. Bodet-Milin C, Touzeau C, Leux C et al. Prognostic impact of (18)F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: retrospective study form the GOELAMS groups. Eur J Nucl Med Mol Imaging 2010; 37: 1633-42.
14. Juweid ME, Stoobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International Harmonization Project in lymphoma. J Clin Oncol 2007; 25: 571-8.
15. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.
16. Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS. Comparison of CT, PET, and PET/CT for staging patients with indolent non-Hodgkin's lymphoma. Mol Imaging Biol 2009; 11: 269-74.
17. Fukukita H, Senda M, Terauchi T et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0. Ann Nucl Med 2010; 24: 325-34.
18. 18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-81.
19. Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotheraphy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-9.
20. Gallamini A, Rigacci L, Merli F et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91: 475-81.
21. Itti E, Lin C, Dupuis J et al. Prognostic value of interim F-18 FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009; 50: 527-33.
22. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two or three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514-23.
23. 18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-52.
24. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50: 122S-50S.